Treatment of Left Ventricular Hypertrophy

First-Line Treatments

The European Society of Cardiology recommends ARBs, particularly losartan, as the preferred first-line agents for LVH regression due to their superior efficacy in reducing left ventricular mass and myocardial fibrosis compared to beta-blockers 1, 2
ACE inhibitors are equally effective as ARBs in reducing LVH and can be considered as alternative first-line agents when ARBs are not tolerated, as suggested by the European Heart Journal 1, 3
Calcium channel antagonists, particularly non-dihydropyridines like verapamil and diltiazem, have demonstrated significant efficacy in LVH regression, according to the European Heart Journal 1, 2
Aldosterone antagonists, such as eplerenone, have shown efficacy equal to ACE inhibitors in reducing LVH, and their combination may be more effective than either agent alone, as reported in the European Heart Journal 1

For obstructive Hypertrophic Cardiomyopathy (HCM), non-vasodilating beta-blockers titrated to maximum tolerated dose are recommended as first-line therapy by the European Heart Journal 4, 5
Verapamil or diltiazem can be used in patients with obstructive HCM who are intolerant to beta-blockers, as suggested by the European Heart Journal 4, 5
Disopyramide can be added to beta-blockers or calcium channel blockers for symptom improvement in patients with obstructive HCM, according to the European Heart Journal 4, 5

The LIFE study demonstrated that losartan was significantly more effective than atenolol in reducing LVH and decreasing myocardial fibrosis, as reported in the European Heart Journal 1, 2
Indapamide, a thiazide-like diuretic, has shown significant efficacy in reducing LVH and was superior to the ACE inhibitor enalapril in one study published in the European Heart Journal 1
The combination of an ACE inhibitor with a diuretic, such as perindopril-indapamide, has shown greater reduction of LV mass than beta-blockers or ACE inhibitors alone, though this was associated with greater blood pressure reduction, according to the European Heart Journal 1

Treatment-induced reduction in left ventricular mass is significantly and independently associated with reduction in major cardiovascular events, stroke, and cardiovascular and all-cause mortality, as reported in the European Heart Journal 1, 3
LVH regression is typically maintained over time but achieves maximum effect after 2-3 years of consistent treatment, according to the European Heart Journal 1

Blood pressure control should remain the primary goal of therapy, as adequate BP reduction is essential for LVH regression, as suggested by the American Heart Association and reported in Circulation and the European Heart Journal 6, 7

ACE inhibitors are considered interchangeable with ARBs as first‑line agents for hypertension‑induced LVH when ARBs are not tolerated, showing comparable efficacy in reducing left ventricular mass. (American College of Cardiology) 8
Thiazide‑type diuretics should not be used as monotherapy in patients with metabolic syndrome; they are effective for LVH regression only when combined with renin‑angiotensin system (RAS) blockade. (American College of Cardiology) 8

In hypertensive patients with LVH, ARBs reduce the recurrence of atrial fibrillation, supporting their use for rhythm‑control adjunctive therapy. (American College of Cardiology) 8
Blood‑pressure control remains a central component of atrial‑fibrillation management in this group, beyond rhythm or rate strategies. (American College of Cardiology) 8
Newer vasodilating β‑blockers (e.g., labetalol, carvedilol, nebivolol) exhibit neutral or favorable metabolic profiles compared with traditional β‑blockers, although outcome data on LVH regression are lacking. (American College of Cardiology) 8

Transthoracic echocardiography is more sensitive than electrocardiography for detecting and tracking LVH; it should assess interventricular septal thickness, posterior wall thickness, end‑diastolic diameter, and calculate left‑ventricular mass. (American College of Cardiology) 9
Echocardiographic reassessment is recommended at 12‑month intervals after initiating therapy because measurable reductions in left‑ventricular mass generally do not appear before one year; annual scans should continue thereafter. (European Heart Journal) 10
During the medication‑titration phase, patients should be reviewed every 2–4 weeks to adjust doses and monitor adverse effects; once target blood pressure is achieved, follow‑up intervals can be extended while maintaining strict blood‑pressure surveillance. (European Heart Journal) 10

Hypertensive LVH must be distinguished from hypertrophic cardiomyopathy (HCM); clinicians should suspect HCM especially in younger individuals or when asymmetric septal hypertrophy is present and pursue appropriate imaging to exclude it. (American College of Cardiology) 11